dpyd-1 encodes the C. elegans ortholog of human DihydroPYrimidine Dehydrogenase (DPYD), which when mutated leads to thymine-uraciluria (OMIM:274270); DPYD-1 is the first and rate-limiting enzyme for uracil and thymine metabolism to 5,6-dihydrouracil and 5,6-dihydrothymine, respectively, and in humans, functions in metabolism of the anti-cancer pyrimidine antagonist 5-fluorouracil (5-FU); in C. elegans, loss of dpyd-1 activity via RNAi results in sensitivity (decreased survival) to 5-FU while conversely, DPYD-1 overexpression affords increased germ cell survivability to 5-FU.
Predicted to enable NADP binding activity; dihydropyrimidine dehydrogenase (NADP+) activity; and uracil binding activity. Predicted to be involved in thymidine catabolic process; thymine catabolic process; and uracil catabolic process. Predicted to be located in cytosol. Human ortholog(s) of this gene implicated in several diseases, including acute lymphoblastic leukemia; dihydropyrimidine dehydrogenase deficiency; and gallbladder cancer. Is an ortholog of human DPYD (dihydropyrimidine dehydrogenase).
Map position created from combination of previous interpolated map position (based on known location of sequence) and allele information. Therefore this is not a genetic map position based on recombination frequencies or genetic experiments. This was done on advice of the CGC.